Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pneumonia I: Introduction

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...

Pneumonia I: Introduction

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...

Atypical Pneumonia

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...

Pneumonia II: Pathophysiology

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:

Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic

Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic

Healthcare-associated infections (HAIs) occur in a healthcare facility while a person receives care for another ailment. This category also includes work-related infections among healthcare staff.
HAIs significantly increase the cost of health care. Extended stays in healthcare institutions, increased disability, increased costs of medications, including specialized antibiotics, and prolonged recovery times add to the patient's expenses and the healthcare institution and funding bodies. Common...

Pneumonia III: Complications and Assessment

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Advancing Pulmonary Fibrosis Care: Integrating Genomic Insights Into Clinical Practice.

Mayo Clinic proceedings·2026

Same author

Opportunities for Human Lung Tissue-Based Studies in Fibrotic ILD Research.

American journal of respiratory and critical care medicine·2026

Same author

Closed cohorts vs open borders: travel medicine lessons from the Ebola and Andes hantavirus outbreaks.

Journal of travel medicine·2026

Same author

An unexpected outbreak at sea: revisiting Hantavirus transmission dynamics.

Journal of travel medicine·2026

Same author

Extracorporeal Membrane Oxygenation for Pneumocystis Pneumonia: Outcomes in Patients From the Extracorporeal Life Support Organization.

Critical care explorations·2026

Same author

The impact of obstructive sleep apnea on idiopathic pulmonary fibrosis clinical outcomes.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine·2026

Search research articles

Related Experiment Video

Updated: May 11, 2026

Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment

Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4⁺ T-cell Immunophenotyping and HIV Reservoir Assessment

Published on: June 23, 2019

Other HIV-associated pneumonias.

Jakrapun Pupaibool¹, Andrew H Limper

¹Division of Infectious Diseases, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.

Clinics in Chest Medicine

|May 25, 2013

Summary

Effective treatments have altered human immunodeficiency virus (HIV)-associated lung infections. This review details uncommon pathogens, diagnostic advances, and prognosis for HIV patients with pulmonary disease.

Area of Science:

Infectious Diseases
Pulmonology
Immunology

Background:

Antiretroviral therapy and antimicrobial prophylaxis have significantly impacted the epidemiology of HIV-associated pulmonary infections.
Pneumonia in patients with acquired immunodeficiency syndrome (AIDS) presents uniquely compared to immunocompetent individuals, affecting clinical presentation, radiographic findings, and treatment strategies.
Diagnosis and prognosis of pulmonary infections in HIV-infected individuals have improved due to advancements in testing and molecular techniques.

Purpose of the Study:

To review pulmonary infections caused by specific uncommon pathogens in patients with HIV/AIDS.
To highlight the changing landscape of HIV-associated lung infections due to modern therapies.
To discuss diagnostic and prognostic improvements in managing these infections.

More Related Videos

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness

Published on: September 28, 2022

Related Experiment Videos

Last Updated: May 11, 2026

Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment

Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4⁺ T-cell Immunophenotyping and HIV Reservoir Assessment

Published on: June 23, 2019

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness

Published on: September 28, 2022

Main Methods:

Literature review focusing on pulmonary infections in HIV-infected patients.
Analysis of data concerning nontuberculosis mycobacteria, cytomegalovirus, fungi, parasites, and uncommon bacterial pneumonias.
Inclusion of information on advances in diagnostic and molecular techniques.

Main Results:

Effective antiretroviral and antimicrobial therapies have changed the incidence, mortality, and epidemiology of HIV-associated pulmonary infections.
Uncommon pathogens like nontuberculosis mycobacteria, cytomegalovirus, fungi (Aspergillus, Cryptococcus, endemic fungi), parasites (Toxoplasma), and bacteria (Nocardia, Rhodococcus) are key concerns.
Improved diagnostic tools enhance the management and outcomes for these patients.

Conclusions:

Pulmonary infections in HIV patients require specialized understanding due to unique presentations and pathogens.
Advances in diagnostics and treatment have improved the prognosis for HIV-associated pulmonary infections.
Continued research and clinical vigilance are essential for managing these complex infections.